Phytochemical Name : Ganoderic acid A (GA-A)

Properties Information
PhytoCAT-ID PhytoCAT-1944
Phytochemical name or plant extracts Ganoderic acid A (GA-A)
PMID 30405790
Literature evidence Ganoderic acid A exerts antitumor activity against MDA-MB-231 human breast cancer cells by inhibiting the Janus kinase 2/signal transducer and activator of transcription 3 signaling pathway.
IUPAC name (2R,6R)-6-[(5R,7S,10S,13R,14R,15S,17R)-7,15-dihydroxy-4,4,10,13,14-pentamethyl-3,11-dioxo-2,5,6,7,12,15,16,17-octahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-methyl-4-oxoheptanoic acid
Phytochemicals’ class or type of plant extracts Triterpenoid
Source of phytochemicals or plant Extracts Ganoderma lucidum
Geographical availability NA
Plant parts NA
Other cancers Breast cancer
Target gene or protein STAT-3
Gene or Protein evidence GA-A suppressed STAT3 target gene expression, including B cell lymphoma-extra-large and Myeloid cell leukemia 1, resulting in elevated levels of proteins associated with mitochondrial apoptosis in addition to inhibitors of cyclin-dependent kinase.
Target pathways JAK-STAT3 signaling pathway
IC50 NA
Potency GA-A treatment inhibited breast cancer cell viability via JAK2/STAT3 downregulation and may regulate associated targets to serve an anti-MDA-MB-231 role, including mitochondrial apoptosis and regulating the expression of cell-cycle-associated factors.
Cell line/ mice model MDA-MB-231
Additional information  Ganoderma triterpenoids isolated from Ganoderma and has been revealed to have an effect on lymphoma growth, as well as in the promotion of cisplatin-induced cell death by inhibiting the JAK-STAT3 signaling pathway. In addition, it suppresses cancer cell proliferation and invasion and induces apoptosis in osteosarcoma
PubChem ID 471002
Additional PMIDs NA
Additional sources of information NA
Safety NA